Presetting CAR-T cells during ex vivo biomanufacturing
Molecular Therapy · 2025-04 · 33 (4) · 1380-1406
DOI: 10.1016/j.ymthe.2025.02.031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025-04. Verfasst von Xu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, The Affiliated Hospital o…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, T-Lymphocytes, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Xuzhou Medical College, Natural Science Research of Jiangsu Higher Education Institutions of China, Jiangsu Province Natural Science Foundation.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. However, it continues to encounter significant obstacles, including treatment relapse and limited efficacy in solid tumors. While effector T cells exhibit robust cytotoxicity, central memory T cells and stem cell-like T cells are essential for in vivo expansion, long-term survival, and persistence. Strategies such as genetic engineering to enhance CAR-T cell efficacy and durability are often accompanied by increased safety risks, which not only raise regulatory approval thresholds but also escalate CAR-T production costs. In contrast, optimizing ex vivo manufacturing conditions represents a more straightforward and practical approach, offering the potential for rapid application to commercially approved CAR-T products and enhancement of their clinical outcomes. This review examines several factors that have been shown to improve T cell memory phenotype and in vivo cytotoxic activity, including cytokines, electrolytes, signaling pathway inhibitors, metabolic modulators, and epigenetic agents. The insights provided will guide the optimization of CAR-T cell industrial production. Furthermore, considerations for selecting appropriate conditions are discussed, balancing effectiveness, cost-efficiency, safety, and regulatory compliance while addressing current challenges in the field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, Jiangsu 221004, China; Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangsu 221002,…
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 Huaihai Road, Xuzhou, Jiangsu 221002, China; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical…
Förderung
- Xuzhou Medical College
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Jiangsu Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Liao, Y., Liu, D., Zheng, J., & Shi, M. (2025). Presetting CAR-T cells during ex vivo biomanufacturing. Molecular Therapy, 33(4), 1380-1406. https://doi.org/10.1016/j.ymthe.2025.02.031
Vancouver
Wang X, Liao Y, Liu D, Zheng J, Shi M. Presetting CAR-T cells during ex vivo biomanufacturing. Molecular Therapy. 2025;33(4):1380-1406. doi:10.1016/j.ymthe.2025.02.031
BibTeX
@article{Wang2025,
author = {Wang, Xu and Liao, Ying and Liu, Dan and Zheng, Junnian and Shi, Ming},
title = {Presetting CAR-T cells during ex vivo biomanufacturing},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {4},
pages = {1380--1406},
doi = {10.1016/j.ymthe.2025.02.031}
}
EUVIMED